Omnitrope approval raises concerns in biotech industry

The FDA's recent approval of a generic version of Pfizer's biotech drug Genotropin has raised concerns in the industry about a possible change in approval of copies of biotech drugs. The biotech industry has long argued its products are too complex to be copied safely, and Congress and the FDA hesitated allowing copies; but the generics industry is pushing for a more flexible policy.

View Full Article in:

San Jose Mercury News (Calif.) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ